Allovir Inc

Change company Symbol lookup

Select an option...

ALVR Allovir Inc

ALIZY Allianz SE

TEO Telecom Argentina SA

BAC Bank of America Corp

TNP Tsakos Energy Navigation Ltd

BFS Saul Centers Inc

ALNY Alnylam Pharmaceuticals Inc

VCNX Vaccinex Inc

XOM Exxon Mobil Corp

ETV Eaton Vance Tax-Managed Buy-Write Opportunities Fund

Go

AlloVir, Inc. is a late clinical-stage cell therapy company. The Company is engaged in developing allogeneic T-cell therapies to treat and prevent viral diseases. Its virus-specific T cell (VST) therapy platform enables to generate VSTs designed to restore immunity in patients with T cell deficiencies. Its product candidate includes Viralym-M (ALVR105), ALVR106, ALVR109, ALVR107 and ALVR108. Its lead product candidate, Viralym-M, is a multi- VST therapy targeting five viruses: BK virus (BKV), cytomegalovirus (CMV), adenovirus (AdV), Epstein-Barr virus (EBV), and human herpesvirus 6 (HHV-6). The ALVR106 is an allogeneic VST therapy developed to target diseases caused by four respiratory viruses: respiratory syncytial virus (RSV), influenza, parainfluenza virus (PIV), and human metapneumovirus (hMPV). VST manufacturing platform enables the reproducible generation of single-virus and multi-virus specific cell therapeutic candidates.